Longeveron Inc. (Nasdaq: LGVN) has reported that its Phase 2b ELPIS II trial of laromestrocel in infants with hypoplastic left heart syndrome did not meet its primary efficacy endpoint.
The randomized, double-blind trial enrolled 40 infants and evaluated laromestrocel as an addition to Stage 2 palliative heart surgery. Participants received either a single dose of the experimental stem-cell therapy injected into the heart during surgery or surgery alone.
According to the September 16 results, the difference between the treatment and control groups in right ventricular ejection fraction after 12 months was negative 0.7 percentage points. The 95% confidence interval ranged from negative 7.3 to positive 5.9 percentage points, with a p-value of 0.8336.
The result did not demonstrate a treatment benefit on the trial’s primary measurement of heart-pumping function. The FDA had also previously told Longeveron that improvement in right ventricular ejection fraction alone would not be sufficient to support regulatory approval.
Longeveron reported several exploratory findings from as-treated analyses. No deaths occurred among laromestrocel-treated patients during the first 12 months, compared with one death in the control group. During follow-up of up to five years, one transplant-free-survival event occurred among 17 treated patients, compared with two among 21 control patients.
The company also reported 12 major adverse cardiovascular events in the treated group and 19 in the control group, representing approximately 31% fewer events. However, that analysis was not statistically significant. Hospitalization burden was similar between the groups, and a company-defined endpoint combining mortality and hospitalization duration also failed to reach statistical significance.
No new safety signals were identified. Treatment-emergent serious adverse events occurred in 64.7% of treated patients and 71.4% of control patients, although investigators did not classify any as related to laromestrocel.
The small study population, use of exploratory as-treated analyses and absence of statistically significant secondary findings limit the conclusions that can be drawn from the numerical differences. Longeveron is continuing to analyze the full dataset and plans to discuss the results with the FDA before deciding whether to continue the hypoplastic-left-heart-syndrome program.
Hypoplastic left heart syndrome is a rare congenital defect in which the left side of the heart is severely underdeveloped. It affects approximately 1,000 infants annually in the United States and generally requires three reconstructive surgeries during the first several years of life.
The trial setback has prompted a broader corporate review. Longeveron plans to appoint an investment bank, reduce spending and evaluate strategic options. The company indicated that it may place greater emphasis on laromestrocel’s aging-related-frailty program while seeking additional funding and revenue opportunities.
“We will work with our advisors to evaluate all options to maximize shareholder value,” CEO Stephen Willard said.
Financial capacity is a significant risk. Longeveron reported approximately $10.1 million in cash as of June 30, 2026, quarterly revenue of $287,000 and a net loss of approximately $6.1 million. Before releasing the trial results, the company expected its existing cash to fund operations only into the fourth quarter of 2026.
Upcoming Catalysts
- Additional analyses from the complete ELPIS II dataset
- An FDA meeting regarding the future of the heart program
- Details about cost reductions and cash-conservation measures
- Appointment of an investment bank or strategic advisor
- Financing, partnership or other strategic transactions
- Further development plans for aging-related frailty
- Long-term transplant-free-survival follow-up
- Possible initiation of a pediatric dilated-cardiomyopathy study
Sources
- Longeveron reports ELPIS II Phase 2b results — September 16, 2026
- Longeveron reports second-quarter 2026 financial results — August 12, 2026
- ELPIS II clinical-trial record, NCT04925024 — ClinicalTrials.gov
- ELPIS II results distributed through GlobeNewswire
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, financial results, SEC filings and the federal clinical-trial registry. Securities discussed or referenced include Longeveron Inc. (Nasdaq: LGVN). Biotech Stocks Daily has not received compensation from Longeveron, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources include Longeveron’s September 16, 2026 ELPIS II announcement, its August 12 financial and corporate update and the ClinicalTrials.gov record for NCT04925024. The reported clinical results originated primarily from Longeveron and have not yet been independently validated through a peer-reviewed publication.
ELPIS II did not meet its primary efficacy endpoint. The reported mortality, transplant-free-survival and cardiovascular-event findings were exploratory, involved small patient numbers and did not establish statistically significant clinical benefit. Numerical differences between the groups should not be interpreted as proof that laromestrocel improves survival or reduces cardiovascular complications.
Laromestrocel remains investigational and is not approved for hypoplastic left heart syndrome, aging-related frailty, Alzheimer’s disease or any other indication. Additional analyses or discussions with the FDA may not produce a viable regulatory path, and Longeveron may reduce, delay or discontinue development programs.
Financial information is reported in U.S. dollars and reflects Longeveron’s position as of June 30, 2026. The company reported limited revenue, continuing operating losses and a cash runway expected to extend only into the fourth quarter of 2026 under its previous operating plan. Additional financing may involve equity issuance and substantial dilution, while a strategic review does not guarantee a partnership, acquisition or other transaction.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
